Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGMS IGM Biosciences	$1.36 +2.7%	$1.23	$0.92 ▼ $22.50	$81.29M	0.48	374,018 shs	526,792 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$68.16 ▼ $131.98	$14.05B	0.69	1.52 million shs	N/A
RCKT Rocket Pharmaceuticals	$2.90 +0.6%	$4.50	$2.19 ▼ $26.98	$309.68M	0.67	2.21 million shs	1.75 million shs
SUPN Supernus Pharmaceuticals	$32.00 -0.2%	$32.26	$25.66 ▼ $40.28	$1.79B	0.7	477,192 shs	212,566 shs
YMAB Y-mAbs Therapeutics	$4.31 +1.1%	$4.47	$3.55 ▼ $16.11	$194.72M	0.51	298,167 shs	81,293 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGMS IGM Biosciences	+2.65%	+11.07%	+8.40%	+19.91%	-78.99%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+90.92%
RCKT Rocket Pharmaceuticals	+0.56%	+11.81%	-2.16%	-43.44%	-85.54%
SUPN Supernus Pharmaceuticals	-0.23%	+2.55%	-0.73%	-2.28%	+23.01%
YMAB Y-mAbs Therapeutics	+1.06%	-10.31%	-11.60%	-5.18%	-62.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IGMS IGM Biosciences	4.4267 of 5 stars	3.0	4.0	4.6	1.9	3.3	0.6
ITCI Intra-Cellular Therapies	0.982 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
RCKT Rocket Pharmaceuticals	4.8511 of 5 stars	4.2	2.0	4.7	1.7	5.0	1.3
SUPN Supernus Pharmaceuticals	2.5748 of 5 stars	2.2	2.0	4.1	2.1	0.0	0.0
YMAB Y-mAbs Therapeutics	2.998 of 5 stars	4.4	1.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGMS IGM Biosciences	1.90	Reduce	$5.50	305.90% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	542.27% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	12.52% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	262.37% Upside

Current Analyst Ratings Breakdown

Latest ITCI, SUPN, YMAB, IGMS, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGMS IGM Biosciences	$2.68M	30.22	N/A	N/A	$0.82 per share	1.65
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
SUPN Supernus Pharmaceuticals	$661.82M	2.71	$4.17 per share	7.67	$18.76 per share	1.71
YMAB Y-mAbs Therapeutics	$87.68M	2.22	N/A	N/A	$2.05 per share	2.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	28.82	22.22	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest ITCI, SUPN, YMAB, IGMS, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGMS IGM Biosciences	N/A	5.71	5.71
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGMS IGM Biosciences	42.79%
ITCI Intra-Cellular Therapies	92.33%
RCKT Rocket Pharmaceuticals	98.39%
SUPN Supernus Pharmaceuticals	N/A
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
IGMS IGM Biosciences	57.00%
ITCI Intra-Cellular Therapies	2.60%
RCKT Rocket Pharmaceuticals	24.76%
SUPN Supernus Pharmaceuticals	8.80%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

ITCI, SUPN, YMAB, IGMS, and RCKT Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 4 at 3:15 AM | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts

July 4 at 3:12 AM | marketbeat.com

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Y mAbs Therapeutics News (YMAB) - Investing.com

June 26, 2025 | investing.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Wesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on YMAB FY2026 Earnings

June 10, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from Analysts

June 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE

June 8, 2025 | marketbeat.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.comQ

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITCI, SUPN, YMAB, IGMS, and RCKT Company Descriptions

IGM Biosciences NASDAQ:IGMS

$1.36 +0.04 (+2.65%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$1.34 -0.02 (-1.48%)

As of 07/3/2025 04:18 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.90 +0.02 (+0.56%)

Closing price 07/3/2025 03:49 PM Eastern

Extended Trading

$2.89 -0.01 (-0.21%)

As of 07/3/2025 04:55 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Supernus Pharmaceuticals NASDAQ:SUPN

$32.00 -0.08 (-0.23%)

Closing price 07/3/2025 01:31 PM Eastern

Extended Trading

$32.00 0.00 (0.00%)

As of 07/3/2025 04:07 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.30 +0.05 (+1.06%)

As of 07/3/2025 02:21 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time